Mylan’s obviousness challenge of erlotinib compound patent fails – US District Judge
On May 1, 2012, the United States District Court for the District of Delaware held that two erlotinib patents, RE 41065 and... Read More
Generics can challenge overly broad use codes – U.S. Supreme Court
On April 17, 2012, the U.S. Supreme Court released its decision in Caraco Pharmaceutical Laboratories Ltd. et al v. Novo Nordisk A/S... Read More
Statements in Clinical Pharmacology section do not induce YASMIN patent infringement – CAFC
On April 16, 2011, the Court of Appeals for the Federal Circuit affirmed that Sandoz, Watson and Lupin do not infringe U.S.... Read More
U.S. Appeals Court overturns District Court’s finding of obviousness (AMRIX/cyclobenzaprine hydrochloride)
On April 16, 2012, the U.S. Court of Appeals for the Federal Circuit (Cephalon et.al. v Mylan Pharmaceuticals et.al.) overturned a Delaware... Read More
Regeneron’s VEGF-TRAP-EYE infringes Genentech’s UK Patent
On March 22, 2012, Justice Floyd of the Chancery Division of the High Court of Justice held that Regneron’s VEGF-TRAP-EYE infringes European... Read More
CAFC affirms obviousness and unenforceability of Sanofi’s docetaxel (TAXOTERE) formulation patents
The Court of Appeals for the Federal Circuit recently affirmed a District Court’s finding that claim 5 of U.S. patent No. 5,750,561... Read More
Trospium (SANCTURA XR) patents obvious – US District Court
On March 31, 2012 Judge Sleet of the District Court for the District of Delaware concluded that the claims of four... Read More
US Court upholds validity of quetiapine formulation patent (SEROQUEL XR)
On March 28, 2012, the U.S. District Court for the District of New Jersey, in a 100 page opinion, held that AstraZeneca’s... Read More
Prometheus’ Patent Claims Directed to Patent-Ineligible Natural Laws – U.S. Supreme Court
On March 20, 2012 the U.S. Supreme Court clarified the scope of patentable subject matter, holding that Prometheus’ patent claims directed to... Read More
Centocor’s ustekinumab infringes Abbott’s human IL-2 antibody patents – US District Judge
On March 9, 2012, the District Court of Massachusetts found, within a series of competing summary judgement motions, that Centocor’s ustekinumab (STELARA)... Read More